Clinical trials: Cocaine Use
Cocaine Use Disorder
Study to Assess Safety, Tolerability, and Interactions of Cocaine and Oral AFQ056
This is a study to assess safety, tolerability and interactions of AFQ056 and cocaine in patients with cocaine use disorder.
- Trial name
- NCT04771143
- Testing
- AFQ056
- Sponsor
- Novartis Pharmaceuticals
Cocaine Use Disorder
A Study to Investigate the Interaction Between TMP-301 and Cocaine.
This will be a randomized, double-blind, placebo-controlled, parallel-group study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of oral TMP-301, given concurrently with cocaine.
- Trial name
- NCT06648668
- Testing
- TMP-301
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Tempero Bio, Inc.
Cocaine Use Disorder
A Study to Evaluate EMB 001 in Subjects With Cocaine Use Disorder
EMB-001 is a combination of 2 drugs: the cortisol synthesis inhibitor, metyrapone (Metopirone®), and the benzodiazepine receptor agonist, oxazepam (original trade name Serax®; now marketed as oxazepam (generic) only).
- Trial name
- NCT04501874
- Testing
- EMB-001
- Where
- 4 sites in United States
- Volunteers
- 82 people
- Sponsor
- Embera NeuroTherapeutics, Inc.
Cocaine-related Disorder
Study to Investigate Whether AFQ056 Reduces Cocaine Use in Patients Diagnosed With Cocaine Use Disorder (CUD)
This study assessed whether AFQ056 had a beneficial effect by reducing cocaine use in Cocaine Use Disorder (CUD) patients as assessed by Timeline Follow-Back cocaine self-report.
- Trial name
- NCT03242928
- Testing
- AFQ056
- Where
- 8 sites in Argentina, Spain and 1 more
- Volunteers
- 68 people
- Sponsor
- Novartis Pharmaceuticals
Cocaine Use Disorder
Phase1, STP7 Cocaine Drug-Drug Interaction Study
This is a double-blind, placebo-controlled, parallel group study to compare the effects of STP7 (mavoglurant) vs placebo control on i.v.
- Trial name
- NCT06273540
- Testing
- STP7 (mavoglurant), Cocaine Hydrochloride
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Stalicla SA
Cocaine Use Disorder, Substance Use Disorders
Multiple Ascending Dose Study of TMP-301 in Healthy Subjects
A PHASE 1, RANDOMIZED, PLACEBO CONTROLLED, MULTIPLE ASCENDING DOSE (MAD) STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF TMP-301 IN HEALTHY SUBJECTS.
- Conditions
- Cocaine Use Disorder, Substance Use Disorders, Healthy Volunteers
- Trial name
- NCT06025396
- Testing
- Cohort 1 - TMP-301, Cohort 2 - TMP-301, Cohort 3 - TMP-301
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Tempero Bio, Inc.
Cocaine Use Disorder, Cocaine Dependence
TDCS for Cocaine Addiction Craving
Transcranial direct current stimulation (tDCS) is a form of non-invasive brain stimulation in which low level electrical currents are applied to the scalp in order to alter brain function.
- Trial name
- NCT03833583
- Testing
- Soterix Medical mini-CT tDCS stimulator
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Soterix Medical
Stimulant Use Disorder
Smartphone Services for Stimulant Use Disorder
This study is testing two approaches to treating Stimulant Use Disorder, or problems with cocaine, crack, methamphetamine, etc. Stimulant Use Disorder is a national epidemic in the U.S.
- Trial name
- NCT07092059
- Testing
- Smartphone digital therapeutic system
- Where
- United States
- Volunteers
- 270 people
- Sponsor
- DynamiCare Health
Addiction, Opioid Dependence
Exploratory Dose Ranging Study Assessing APH-1501 for the Treatment of Opioid Addiction
The purpose of this study is determine the safety, efficacy and tolerability of a novel drug APH-1501 as a pharmacotherapy for Opioid Dependence. The investigators will evaluate the safety of escalating doses APH-1501.
- Conditions
- Addiction, Opioid Dependence, Opioid Withdrawal
- Trial name
- NCT03813095
- Testing
- APH-1501
- Volunteers
- 32 people
- Sponsor
- Aphios
Cocaine Use Disorder
Single Dose Crossover Comparative Bioavailability and Food Effect Study of Two EMB-001 Formulations
This is a study of EMB-001 (a combination of two FDA-approved drugs, metyrapone and oxazepam) in healthy adults.This is a Phase 1, single dose, 3-period, 3-sequence, crossover study in 9 healthy male and female (not of…
- Trial name
- NCT03404817
- Testing
- Original formulation EMB-001, New formulation EMB-001
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Embera NeuroTherapeutics, Inc.
Cocaine Use Disorder, Tobacco Use Disorder
Single and Multiple Rising Dose Study of Safety and PK of Metyrapone/Oxazepam Combination (EMB-001)
This is a study of EMB-001 (a combination of two FDA-approved drugs, metyrapone and oxazepam) in otherwise healthy adults who are regular cigarette smokers.
- Trial name
- NCT02406066
- Testing
- metyrapone & oxazepam
- Where
- 2 sites in United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Embera NeuroTherapeutics, Inc.
Cocaine Use Disorder, Cocaine Dependence
TDCS to Reduce Craving in Cocaine Addiction- Phase 2 Study
Transcranial direct current stimulation (tDCS) is a form of non-invasive brain stimulation in which low level electrical currents are applied to the scalp in order to alter brain function.
- Trial name
- NCT04994821
- Testing
- transcranial direct current stimulator (tDCS), Cognitive Reappraisal
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Soterix Medical
Cocaine Use, Cocaine Intoxication
Comparing Efficacy & Safety Of TNX-1300 To Placebo With UC For Treatment Of Acute Cocaine Intoxication In ED Subjects (CATALYST)
This is a Phase 2 single-blind, randomized, multicenter study to compare the efficacy and safety of a single dose of TNX-1300 to placebo with usual care in patients with acute cocaine intoxication within the emergency department…
- Conditions
- Cocaine Use, Cocaine Intoxication, Cocaine Toxicity, Cocaine Abuse
- Trial name
- CATALYST (NCT06045793)
- Testing
- TNX-1300 (Injection)
- Where
- 6 sites in United States
- Volunteers
- 3 people
- Sponsor
- Tonix Pharmaceuticals, Inc.
Substance Use Disorders, Opioid Use Disorder
Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders
The overarching goal of this study phase, Phase II component is to implement Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders (EDITOR) device in substance use disorder (SUD)…
- Conditions
- Substance Use Disorders, Opioid Use Disorder, Alcohol Use Disorder, Cocaine Use Disorder
- Trial name
- EDITOR (NCT06434818)
- Testing
- EDITOR (CBOT with olfactory stimulants, OFC tasks & remote monitoring of treatment compliance), CBOT with olfactory stimulants & OFC tasks
- Where
- 3 sites in United States
- Volunteers
- 300 people
- Sponsor
- Evon Medics LLC
Cocaine Use Disorder
A Study of Metyrapone and Oxazepam Combination Product (EMB-001) and Cocaine
EMB-001 is a combination of 2 drugs: the cortisol synthesis inhibitor, metyrapone (Metopirone®), and the benzodiazepine receptor agonist, oxazepam (original trade name Serax®; now marketed as oxazepam (generic) only).
- Trial name
- NCT02856854
- Testing
- EMB-001, Cocaine IV, Saline IV
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Embera NeuroTherapeutics, Inc.